Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross ProceedsGlobeNewsWire • 12/07/23
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/09/23
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin CarcinomasGlobeNewsWire • 11/09/23
Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor ControlGlobeNewsWire • 11/03/23
Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)GlobeNewsWire • 10/12/23
Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894GlobeNewsWire • 10/11/23
Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer InstituteGlobeNewsWire • 08/21/23
Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/10/23
Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq RulesPRNewsWire • 06/02/23
Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq RulesPRNewsWire • 05/31/23
Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer InstitutePRNewsWire • 05/24/23
Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor CellsPRNewsWire • 05/18/23
Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin CarcinomasPRNewsWire • 05/16/23
Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdatePRNewsWire • 05/11/23
Phio Pharmaceuticals Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesPRNewsWire • 04/20/23
Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesPRNewsWire • 04/18/23
Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business UpdatePRNewsWire • 03/22/23
Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive OfficerPRNewsWire • 02/22/23